hepatocellular carcinoma

Recent Advances in Systemic Therapy for Hepatocellular Carcinoma Bookmark

This review article in the academic research journal Biomarker Research discusses how combining immunotherapy and targeted therapies provides new hope for people with hepatocellular carcinoma.

.

Treatment Approaches for Advanced Hepatocellular Carcinoma: Insight From the 2022 Gastrointestinal Cancers Symposium Bookmark

In this article for Cancer Therapy Advisor, Dr. Shaalan Beg shares updates from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium on treatments for advanced hepatocellular carcinoma.

.

Hepatocellular Carcinoma in 2021: An Exhaustive Update Bookmark

This exhaustive scientific review was published by Cureus in 2021, but remains relevant now. It explores current molecular understanding of hepatocellular carcinoma—the most common type of cancer that starts in the liver—as well as a very large range of diagnostic and treatment options. 

.

New Approvals for Liver Cancer Mark ‘Golden Age’ of Treatment Bookmark

Reported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).

.

Hepatocellular Carcinoma (HCC)—An Overview Bookmark

Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

This 2020 encyclopedic approach to all of the many diagnostic and therapeutic options available for primary hepatocellular carcinoma leaves no stone unturned. (Free registration required, written with a physician audience in mind.)

.

Efficacy and Safety of Sorafenib Plus Vitamin K Treatment for Hepatocellular CarcinomA: A Phase II, Randomized Study Bookmark

This scientific research paper published in the journal Cancer Medicine reports that the drug sorafenib has shown some effectiveness against hepatocellular carcinoma in a clinical trial, and that adding vitamin K2 enhanced that effectiveness.

.

Targeted Therapy for Hepatocellular Carcinoma Bookmark

This scientific review paper published in the journal Signal Transduction and Targeted Therapy discusses recent research into newer medications that show promise as targeted therapies for some cases of primary hepatocellular carcinoma, following molecular testing.

.

Innovent Biologics’s TYVYT/Byvasda combo shows survival benefit in late-stage liver cancer study Bookmark

Article from Seeking Alpha curated by Contributing Editor George Lundberg, MD, who notes: 

In a phase 3 clinical trial, a new drug combination improved both overall survival and progression-free survival for people with hepatocellular carcinoma.

.

Atezolizumab Plus Bevacizumab vs Sorafenib in Treatment-Naive Patients With Unresectable Hepatocellular Carcinoma Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

In a clinical trial, a combination of the drugs atezolizumab and bevacizumab improved both progression-free survival and overall survival in advanced hepatocarcinoma (the most common form of liver cancer), with fewer adverse effects. These findings were reported in the New England Journal of Medicine.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

In a clinical trial, a new combination therapy conferred better response rates, progression-free survival, and overall survival than standard sorafinib for unresectable hepatocellular carcinoma.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.